New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

A recent survey reveals the foods that people are less likely to eat once they start taking GLP-1 medications like Ozempic.

The following text highlights some of these precautions. Boxed warning: Risk of thyroid cancer Semaglutide (the active ingredient in Ozempic and Wegovy) has a boxed warning for a possible risk of ...

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

A new analysis of FDA adverse event reports suggests a potential link between tirzepatide and thyroid cancer. Learn what this ...

Animal studies have shown that using liraglutide (the active ingredient in Saxenda) or semaglutide (the active ingredient in Ozempic) may increase the risk of thyroid cancer. However, the risk of ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease. ️ The ...

Semaglutide use associated with increased risk for NAION at the 2-, 3-, and 4-year time point from the index date.